Full Text View
Tabular View
No Study Results Posted
Related Studies
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)
This study has been completed.
Study NCT01478269   Information provided by Fondazione Italiana Linfomi ONLUS

First Received on October 12, 2011.   Last Updated on November 22, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
B-Cell Lymphomas
Additional conditions recognized in this trial
Aggression
Lymphoma
Lymphoma, B-Cell
More general conditions related to this trial
Behavioral Symptoms
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Additional drug interventions recognized in this trial
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Fondazione Italiana Linfomi ONLUS


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services